| DATE |
HEADLINE |
SUMMARY |
| October, 2023 |
Prevalence of Australians exposed to potentially cardiotoxic cancer medicines: a population-based cohort study |
Cardiovascular disease and cancer are major death causes, with some cancer drugs increasing heart disease risk. A study from 2005 to 2021 found that over 108,000 Australians were given such cardiotoxic cancer medicines, with the exposure rate rising significantly. This highlights the need for awareness and planning regarding cancer treatment side effects in Australia. link |
| September, 2023 |
Family communication and results disclosure after germline sequencing: A mixed methods study |
The study examined how individuals discuss genetic health risks with their families. Most participants felt the need to inform close relatives. However, understanding and relaying this data was often difficult. It’s suggested that healthcare professionals and tools like chatbots can help simplify and enhance these crucial conversations. link |
| March 13, 2023 |
Recent advances on anti-angiogenic multi-receptor tyrosine kinase inhibitors in osteosarcoma and Ewing sarcoma |
Osteosarcoma and Ewing sarcoma are common bone cancers in the young. New drugs targeting multiple growth pathways of these cancers show promise, but none are officially approved for treatment yet. The article evaluates the effectiveness and side effects of these drugs, highlighting the need for further research to determine the best use for improved patient outcomes. link |
| January 19, 2023 |
Heritable defects in telomere and mitotic function selectively predispose to sarcomas |
Researchers studied the genes of people with sarcoma and compared them to those without the disease. They discovered that certain genetic changes, especially in parts of DNA that deal with cell division and protecting the ends of DNA strands, can increase the risk of getting these cancers. This means that some people might be more likely to develop sarcomas due to their genetic makeup. link |
| June 23, 2021 |
Precision medicine becomes more accessible for Australians with cancer |
A new resource developed at the Garvan Institute of Medical Research and The Kinghorn Cancer Centre for oncologists could help make targeted cancer therapies more accessible for Australian patients. The TOPOGRAPH (Therapy-Oriented Precision Oncology Guidelines for Recommending Anti-cancer Pharmaceuticals) database is an online tool that catalogues oncology research to streamline the process of recommending therapeutic treatments in precision cancer medicine. link |
| June 3, 2021 |
Gene Behind Childhood Bone Cancer Uncovered |
Researchers based at the University of North Carolina at Chapel Hill have discovered that the gene OTUD7A controls a cancer-causing protein in Ewing sarcoma, a type of bone cancer mostly impacting children. link |
| April 21, 2021 |
Messenger RNA Vaccines: Beckoning of a New Era in Cancer Immunotherapy |
Messenger RNA (mRNA) vaccines are a relatively new class of vaccines. They combine the potential of mRNA to encode for almost any protein with an excellent safety profile and a flexible production process. Recently, 2 mRNA vaccines were approved for the first time for human use – to prevent COVID-19 infection – bringing excitement for the future possibilities of this approach for cancer immunotherapy as well as for preventing other infectious diseases. link |
| March 30, 2021 |
FDA grants fast track designation to annamycin for sarcoma lung metastases |
The FDA granted fast track designation to annamycin for the treatment of patients with lung metastases from soft tissue sarcoma, according to a press release from the agent’s manufacturer. link |
